Comparison of MECHANISM of Early and Late Vascular Responses Following Treatment of ST-elevation Acute Myocardial Infarction With Two Different Everolimus-eluting Stents: Randomized Controlled Trial Between Biodegradable Polymer and Durable Polymer Stent (MECHANISM-AMI-RCT)

Exclusion Criteria

• •1. When the follow-up after 12 months is considered difficult (the patient's residence should also be considered)
• •2. When there is no obvious ACS finding in angiography (decisions should be left to operator)
• •3. Patients with shock
• •4. Patients whose culprit lesion is the left main coronary trunk
• •5. Lesion with the reference vascular diameter of \<2.0 mm or ≥4.5 mm visually
• •6. AMI that occurred newly at the site where a stent has already been placed
• •7. Chronic renal failure in which the serum creatinine concentration at visit is ≥2.0 mg/dL
• •8. Patients undergoing hemodialysis
• •9. Tumor-bearing patients whose life prognosis is expected to be within 2 years
• •10. Patients for whom the surgical operation requiring withdrawal of antiplatelet drug is scheduled within 3 months
• •11. Female patients during pregnancy or scheduled to be pregnant
• •12. Patients with a past history of the side effect of aspirin, clopidogrel or prasugrel (when the patient is confirmed for the safety of ticlopidine, this does not apply even if there is the side effect of clopidogrel or prasugrel)